UroGen Pharma (URGN) Operating Income (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Operating Income data on file, last reported at -$20.3 million in Q1 2026.

• Quarterly Operating Income rose 45.11% year-over-year to -$20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.2 million (changed 0.24% YoY) and the FY2025 annual result came in at -$124.9 million, down 29.01% from the prior year.
• Operating Income fell to -$20.3 million in Q1 2026, from -$19.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$13.5 million in Q3 2023 to a low of -$41.4 million in Q2 2025.
• A 5-year average of -$22.7 million and a median of -$20.3 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2024 — Operating Income slumped 89.32% — and 2026, when it surged 45.11%.
• Tracing URGN's Operating Income over 5 years: stood at -$20.3 million in 2022, then grew by 27.97% to -$14.6 million in 2023, then slumped by 89.32% to -$27.7 million in 2024, then surged by 30.89% to -$19.1 million in 2025, then declined by 6.01% to -$20.3 million in 2026.
• The last three Operating Income figures came in at -$20.3 million (Q1 2026), -$19.1 million (Q4 2025), and -$27.4 million (Q3 2025), per Business Quant data.